



US008058238B2

(12) **United States Patent**  
**Kelleher et al.**

(10) **Patent No.:** **US 8,058,238 B2**  
(45) **Date of Patent:** **Nov. 15, 2011**

(54) **HIGH PURITY LIPOPEPTIDES**

(75) Inventors: **Thomas Kelleher**, Weston, MA (US);  
**Jan-Ji Lai**, Westborough, MA (US);  
**Joseph P. DeCoursey**, Charlestown, MA  
(US); **Paul Lynch**, Arlington, MA (US);  
**Maurizio Zenoni**, Milan (IT); **Auro**  
**Tagliani**, Pavia (IT)

(73) Assignee: **Cubist Pharmaceuticals, Inc.**,  
Lexington, MA (US)

(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **11/739,180**

(22) Filed: **Apr. 24, 2007**

(65) **Prior Publication Data**

US 2007/0191280 A1 Aug. 16, 2007

**Related U.S. Application Data**

(60) Continuation of application No. 10/747,485, filed on  
Dec. 29, 2003, now abandoned, which is a division of  
application No. 09/735,191, filed on Nov. 28, 2000,  
now Pat. No. 6,696,412.

(60) Provisional application No. 60/177,170, filed on Jan.  
20, 2000.

(51) **Int. Cl.**

**C07K 7/50** (2006.01)

**C07K 7/00** (2006.01)

(52) **U.S. Cl.** ..... **514/9**; 514/11; 514/2; 514/14;  
530/317; 530/322; 530/344; 435/886

(58) **Field of Classification Search** ..... 514/9, 11,  
514/2, 14; 530/317, 322, 344; 435/886  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,331,594 A 5/1982 Hamill et al.  
4,482,487 A 11/1984 Abbott et al.  
4,524,135 A 6/1985 Abbott et al.  
4,537,717 A 8/1985 Abbott et al.  
RE32,310 E 12/1986 Debono  
RE32,311 E 12/1986 Debono  
RE32,333 E 1/1987 Hamill et al.  
RE32,455 E 7/1987 Hamill et al.  
4,800,157 A 1/1989 Eaton et al.  
4,874,843 A 10/1989 Baker  
4,882,164 A 11/1989 Ferro et al.  
4,885,243 A 12/1989 Huber et al.  
5,271,935 A 12/1993 Franco et al.  
5,387,670 A 2/1995 Roy et al.  
5,573,936 A 11/1996 Kreuzman et al.  
5,629,288 A 5/1997 Lattrell et al.  
5,912,226 A 6/1999 Baker et al.  
5,955,509 A 9/1999 Webber et al.

FOREIGN PATENT DOCUMENTS

EP 0095295 A1 11/1983  
EP 0178152 A2 4/1986  
EP 0294990 A2 12/1988  
EP 0337731 61 10/1989  
EP 0386951 A2 9/1990  
WO WO 99/27954 6/1999  
WO WO 99/27957 6/1999  
WO WO 99/43700 9/1999  
WO WO 00/18419 4/2000  
WO WO 01/44271 6/2001  
WO WO 01/44272 6/2001  
WO WO 01/44274 6/2001

OTHER PUBLICATIONS

DeBono, M. et al.; "Enzymatic and Chemical Modifications of  
Lipopeptide Antibiotic A21978C: The Synthesis and Evaluation of  
Daptomycin (LY146032)," J. Antibiotics; 41; 1988; pp. 1093-1105.  
Desai, J. D., et al.; "Microbial Production of Surfactants and Their  
Commercial Potential," Microbiology and Molecular Biology  
Review, vol. 61; No. 1; 1997; pp. 47-64; American Society for  
Microbiology.  
Fostel, Jennifer M., et al.; "Emerging Novel Antifungal Agents,"  
DDT; vol. 5; No. 1; Jan. 2000; pp. 25-32; Elsevier Science Ltd.  
Horowitz, Sarah, et al.; "Isolation and Characterization of a Surfactant  
Produced by *Bacillus licheniformis* 86," J. Industrial Microbiol.; 6;  
1990; pp. 243-248; Society for Industrial Microbiology.  
Kirsch, Lee E., et al.; "Kinetics of the Aspartyl Transposition of  
Daptomycin, a Novel Lipopeptide Antibiotic," Pharmaceutical  
Research; vol. 6; No. 5; 1989; pp. 387-393; Plenum Publishing  
Corporation.  
Lasic, Dan D., et al.; "Novel Applications of Liposomes," Trends  
Biotechnology; vol. 16; Jul. 1998; pp. 307-321; Elsevier Science Ltd.  
Lasic, Danilo D., et al.; "Mixed Micelles in Drug Delivery," Nature;  
vol. 355; Issue No. 6357; Jan. 16, 1992; pp. 279-280.  
Lin, S.-C. et al., "General Approach for the Development of High-  
Performance Liquid Chromatography Methods for Biosurfactant  
Analysis and Purification," J. Chromatography; 825; 1998; pp. 149-  
159.  
Lin, S.-C. et al.; "Recovery and Purification of the Lipopeptide  
Biosurfactant of *Bacillus subtilis* by Ultrafiltration," Biotechnology  
Techniques; vol. 11; No. 6; Jun. 1997; pp. 413-416; Chapman Hall.

(Continued)

Primary Examiner — Chih-Min Kam

(57) **ABSTRACT**

The invention discloses highly purified daptomycin and to  
pharmaceutical compositions comprising this compound.  
The invention discloses a method of purifying daptomycin  
comprising the sequential steps of anion exchange chroma-  
tography, hydrophobic interaction chromatography and  
anion exchange chromatography. The invention also dis-  
closes a method of purifying daptomycin by modified buffer  
enhanced anion exchange chromatography. The invention  
also discloses an improved method for producing daptomycin  
by fermentation of *Streptomyces roseosporus*. The invention  
also discloses high pressure liquid chromatography methods  
for analysis of daptomycin purity. The invention also dis-  
closes lipopeptide micelles and methods of making the  
micelles. The invention also discloses methods of using  
lipopeptide micelles for purifying lipopeptide antibiotics,  
such as daptomycin. The invention also discloses using  
lipopeptide micelles therapeutically.

## OTHER PUBLICATIONS

- Mulligan, Catherine N., et al., "Recovery of Biosurfactants by Ultrafiltration," J. Chem. Tech. Biotechnology.; 47; 1990; pp. 23-29; Society of Chemical Industry; Printed in Great Britain.
- Schott, H.; "Colloidal Dispersions," Remington: The Science and Practice of Pharmacy; vol. 1; 19th Edition; 1995; pp. 252-277; Mack Publishing Company; Easton, Pennsylvania USA.
- Shaw, Duncan J.; "Liquid-Gas and Liquid-Liquid Interfaces," Introduction to Colloid and Surface Chemistry; 1989; pp. 64-114; 4th Edition; Butterworth-Heinemann Ltd. Great Britain.
- Sterling, John; "Membrane-Based System Combines Selective Separation with High-Volume Throughput," Genetic Engineering News; vol. 19; No. 20; Nov. 15, 1999; pp. 1, 34.
- Supersaxo, Andreas et al.; "Mixed Micelles as Proliposomal, Lymphotropic Drug Carrier," Pharmaceutical Research; vol. 8; No. 10; 1991; pp. 1286-1291; Plenum Publishing Corporation.
- Sweadner, Kathleen J. et al., "Filter Removal of Endotoxin (Pyrogens) In Solution in Different States of Aggregation," Applied and Environmental Microbiology; vol. 34; No. 4; 1977; pp. 382-385; American Society for Microbiology; Printed in the USA.
- Tally, F.P., et al.; "Daptomycin: A Novel Agent for Gram Positive Infections," Exp. Opin. Invest. Drugs; 8; 1999; 1223-1238.
- Thimon, L et al., "Surface-Active Properties of Antifungal Lipopeptides Produced by *Bacillus subtilis*," J. Am. Oil Chem. Soc.; 69; 1992; pp. 92-93.
- Yakimov, Michell M. et al.; "Characterization of a New Lipopeptide Surfactant Produced by Thermotolerant and Halotolerant Subsurface *Bacillus licheniformis* BAS50," Applied and Environmental Microbiology; vol. 61; No. 5; 1995; pp. 1706-1713; American Society for Microbiology.
- U.S. Appl. No. 07/060,148, filed Jun. 10, 1987, Baker et al.
- Agreement between Cubist Pharmaceuticals, Inc. and Eli Lilly and Company dated Nov. 7, 1997. (Redacted form from SEC Edgar).
- Agreement between Cubist Pharmaceuticals, Inc. and Eli Lilly and Company dated Oct. 6, 2000. (Redacted form from SEC Edgar).
- Assignment of US Re 39,071 from Eli Lilly and Company to Cubist Pharmaceuticals, Inc. recorded on Apr. 23, 2007. Reel/Frame: 019181/0916.
- Maio, et al., "Daptomycin biosynthesis in *Streptomyces roseosporus*: cloning and analysis of the gene cluster and revision of peptide stereochemistry," Microbiology, (vol. 151), (p. 1507-1523), (2005).
- Molloy, M. et al., Abstract, "Structure & Anhydro-Daptomycin and Iso-Daptomycin," ACS 200th Meeting, 1990.
- Molloy, M. et al., Poster, "Structure & Anhydro-Daptomycin and Iso-Daptomycin," ACS 200th Meeting, 1990.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.